Primary myelofibrosis with concurrent CALR and MPL mutations: A case report
- PMID: 33344552
- PMCID: PMC7716329
- DOI: 10.12998/wjcc.v8.i22.5618
Primary myelofibrosis with concurrent CALR and MPL mutations: A case report
Abstract
Background: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by recurrent mutations in the JAK2, CALR, and MPL genes. The CALR and MPL co-mutation is very rare. To our knowledge, no more than five cases have been reported. Here, we report a case of PMF in which a CALR and MPL co-mutation was detected by next-generation sequencing (NGS) technology, and a literature review was performed.
Case summary: A 73-year-old woman was admitted to our hospital in 2018 due to abdominal distension. The patient had splenomegaly, lymphadenopathy, leukopenia, anemia, and immature granulocytes in peripheral blood. There were dacrocytes and atypical megakaryocytes in bone marrow, and megakaryocytic proliferation was very active, accompanied by reticulin fibrosis grade 2. By NGS analysis of the bone marrow sample, we detected mutations in CALR, MPL, and PIK3RI, while JAK2 V617F and BCR-ABL were negative. Therefore, the patient was diagnosed with PMF and received oral ruxolitinib. However, the spleen and hematologic responses were poor. We review the literature, analyze previous reports of the mutation sites in our patient and differences between our patient and other reported cases of co-mutated CALR and MPL genes, and discuss the reason why the CALR and MPL co-mutations are rare and possible mechanisms and their impact on the prognosis of patients.
Conclusion: CALR and MPL mutations can be concurrent in MPN, but they are rare. The use of NGS may help to identify more patients with co-mutated CALR and MPL genes. This will help to further explore the mechanism and its impact on these patients to develop appropriate treatment strategies.
Keywords: CALR; Case report; Co-mutation; MPL; Next-generation sequencing; Primary myelofibrosis.
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
Figures



Similar articles
-
[Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].Zhonghua Yi Xue Za Zhi. 2015 May 12;95(18):1369-73. Zhonghua Yi Xue Za Zhi. 2015. PMID: 26178351 Chinese.
-
JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East.Iran J Pathol. 2021 Spring;16(2):190-194. doi: 10.30699/IJP.2021.136458.2495. Epub 2021 Jan 24. Iran J Pathol. 2021. PMID: 33936230 Free PMC article.
-
[Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Feb;25(1):151-156. doi: 10.7534/j.issn.1009-2137.2017.01.027. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017. PMID: 28245393 Chinese.
-
Presence of triple positive driver mutations in JAK2, CALR and MPL in primary myelofibrosis: a case report and literature review.Hematology. 2024 Dec;29(1):2402106. doi: 10.1080/16078454.2024.2402106. Epub 2024 Sep 13. Hematology. 2024. PMID: 39268974 Review.
-
Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Acta Haematol. 2015. PMID: 25116092 Review.
Cited by
-
High-resolution melting assay for rapid, simultaneous detection of JAK2, MPL and CALR variants.J Clin Pathol. 2024 Aug 16;77(9):639-644. doi: 10.1136/jcp-2023-208861. J Clin Pathol. 2024. PMID: 37156613 Free PMC article.
-
Primary myelofibrosis with concurrent MPL and atypical JAK2 mutations.J Hematop. 2025 Jun 4;18(1):27. doi: 10.1007/s12308-025-00642-w. J Hematop. 2025. PMID: 40467885
-
A Rare Co-Occurrence of Triple Mutations in JAK2, CALR, and MPL in the Same Patient with Myelofibrosis.Case Rep Hematol. 2022 Feb 21;2022:4579122. doi: 10.1155/2022/4579122. eCollection 2022. Case Rep Hematol. 2022. PMID: 35237453 Free PMC article.
-
Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing.Life (Basel). 2021 Oct 30;11(11):1158. doi: 10.3390/life11111158. Life (Basel). 2021. PMID: 34833034 Free PMC article. Review.
References
-
- Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28:1472–1477. - PubMed
-
- Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220–2228. - PubMed
-
- McGaffin G, Harper K, Stirling D, McLintock L. JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Haematol. 2014;167:276–278. - PubMed
-
- Pardanani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, Vannucchi AM, Tefferi A. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia. 2011;25:1834–1839. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous